Our target potential upside is 21% to 54% in the next 4-6 months.
Coeur Mining (NYSE: CDE) Just Broke Out
by
•Our target potential upside is almost 30% to 122% in the next 3-6 months.
Look For Radius Health (NASDAQ: RDUS) to Surge in the Short-Term
by
•Our target potential upside is nearly 26% to 70% in the next 4-6 months.
Ionis Pharmaceuticals (NASDAQ: IONS) Broke Out and Has the Potential to Surge Higher
by
•Our target potential upside is almost 13% to 32% in the next 3-6 months.
Ligand Pharmaceuticals (NASDAQ: LGND) Could Move Higher in the Short-Term
by
•Our target potential upside is 16% to 26% in the next 3-6 months.
Concert Pharmaceuticals (NASDAQ: CNCE) Could Make an Upmove in the Near-Term
by
•Our target potential upside is nearly 11% to 33% in the next 3-5 months.
Sangamo Therapeutics (NASDAQ: SGMO) Just Broke Out on High Volume
by
•Our target potential upside is nearly 27% to 88% in the next 3-6 months.
Eli Lilly (NYSE: LLY) Just Broke Out
by
•Our target potential upside is nearly 7% to 13% in the next 3-6 months.
Equifax (NYSE: EFX) Just Broke Out on High Volume
by
•Our target potential upside is 5% to 17% in the next 4-6 months.
Constellation Pharmaceuticals (NASDAQ: CNST) Looks Ready for a Short-Term Price Bump
by
•Our target potential upside is 29% to 61% in the next 3-6 months.